BioCentury
ARTICLE | Clinical News

Lumiliximab: Suspended Phase II/III enrollment

October 26, 2009 7:00 AM UTC

Biogen Idec disclosed that it stopped recruitment in the Phase II/III LUCID trial of lumiliximab to treat CLL after a strategic review of the program determined that the trial would not support regist...